| Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis Y Xia, D Stadler, J Lucifora, F Reisinger, D Webb, M Hösel, T Michler, ... Gastroenterology 150 (1), 194-205, 2016 | 372 | 2016 |
| The global hepatitis B virus genotype distribution approximated from available genotyping data S Velkov, JJ Ott, U Protzer, T Michler Genes 9 (10), 495, 2018 | 199 | 2018 |
| Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice T Michler, AD Kosinska, J Festag, T Bunse, J Su, M Ringelhan, H Imhof, ... Gastroenterology 158 (6), 1762-1775. e9, 2020 | 127 | 2020 |
| Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing J Zecha, CY Lee, FP Bayer, C Meng, V Grass, J Zerweck, K Schnatbaum, ... Molecular & Cellular Proteomics 19 (9), 1503-1522, 2020 | 100 | 2020 |
| One-vector system for multiplexed CRISPR/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors M Schiwon, E Ehrke-Schulz, A Oswald, T Bergmann, T Michler, U Protzer, ... Molecular Therapy Nucleic Acids 12, 242-253, 2018 | 77 | 2018 |
| siRNA therapeutics against respiratory viral infections—What have we learned for potential COVID‐19 therapies? A Mehta, T Michler, OM Merkel Advanced healthcare materials 10 (7), 2001650, 2021 | 68 | 2021 |
| Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread S Ambike, CC Cheng, M Feuerherd, S Velkov, D Baldassi, SQ Afridi, ... Nucleic Acids Research 50 (1), 333-349, 2022 | 65 | 2022 |
| New pharmacological strategies to fight enveloped viruses K Wisskirchen, J Lucifora, T Michler, U Protzer Trends in pharmacological sciences 35 (9), 470-478, 2014 | 60 | 2014 |
| Novel viral and host targets to cure hepatitis B C Ko, T Michler, U Protzer Current opinion in virology 24, 38-45, 2017 | 57 | 2017 |
| Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms T Michler, M Storr, J Kramer, S Ochs, A Malo, S Reu, B Göke, C Schäfer American Journal of Physiology-Gastrointestinal and Liver Physiology 304 (2 …, 2013 | 51 | 2013 |
| Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes D Baldassi, S Ambike, M Feuerherd, CC Cheng, DJ Peeler, DP Feldmann, ... Journal of Controlled Release 345, 661-674, 2022 | 44 | 2022 |
| Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter PAC Wing, PJ Liu, JM Harris, A Magri, T Michler, X Zhuang, H Borrmann, ... Journal of hepatology 75 (1), 64-73, 2021 | 38 | 2021 |
| Blocking sense‐strand activity improves potency, safety and specificity of anti‐hepatitis B virus short hairpin RNA T Michler, S Große, S Mockenhaupt, N Röder, F Stückler, B Knapp, C Ko, ... EMBO molecular medicine 8 (9), 1082-1098, 2016 | 31 | 2016 |
| Hepatitis B virus infection enhances susceptibility toward adeno‐associated viral vector transduction in vitro and in vivo M Hösel, J Lucifora, T Michler, G Holz, M Gruffaz, S Stahnke, F Zoulim, ... Hepatology 59 (6), 2110-2120, 2014 | 27 | 2014 |
| PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis b T Bunse, AD Kosinska, T Michler, U Protzer Biomolecules 12 (3), 470, 2022 | 18 | 2022 |
| Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models PJ Liu, JM Harris, E Marchi, V D’arienzo, T Michler, PAC Wing, A Magri, ... Scientific Reports 10 (1), 14101, 2020 | 18 | 2020 |
| Global occurrence of clinically relevant hepatitis b virus variants as found by analysis of publicly available sequencing data S Velkov, U Protzer, T Michler Viruses 12 (11), 1344, 2020 | 17 | 2020 |
| Methods for the treatment of subjects having a hepatitis b virus (HBV) infection L Sepp-Lorenzino, U Protzer, T Michler US Patent 11,324,820, 2022 | 7 | 2022 |
| Systematic analysis of RNAi-accessible SARS-CoV-2 replication steps identifies ORF1 as promising target S Ambike, C Cheng, S Afridi, M Feuerherd, P Hagen, V Grass, O Merkel, ... | 7 | 2020 |
| Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B T Michler, A Kosinska, T Bunse, M Heikenwälder, D Grimm, S Milstein, ... Journal of Hepatology 66 (1), S112, 2017 | 7 | 2017 |